The Korea Times
WASHINGTON — The U.S. Department of Justice said on Thursday that it was immediately loosening restrictions on some marijuana products and accelerating the process of reclassifying the drug as less dangerous in one of the biggest changes to U.S. drug policy in decades. The Trump administration immediately moved FDA-approved marijuana products and state-regulated medical marijuana from a group of drugs classified as highly addictive to one that has a low to moderate potential for abuse. Acting Attorney General Todd Blanche said the U.S. government would also fast-track a broader consideration of marijuana under federal law, moving the psychoactive plant from a so-called Schedule I drug to a Schedule III. The move would list marijuana alongside common painkillers, ketamine and testosterone rather than its current status with drugs like heroin and LSD. The measures are likely to reshape the pot industry, lowering barriers to researching the drug's potential health benefits, easing tax burdens and making it easier for firms to secure funding. The announcement does not legalize marijuana a
Go to News Site